GLP-1 Receptor Agonist Use and Clinical Outcomes in Patients With Hidradenitis Suppurativa

This cohort study examines mortality, major cardiovascular events, and systemic complications in persons with hidradenitis suppurativa taking glucagon-like peptide-1 (GLP-1) receptor agonists.

Corresponding Author: Jacek C. Szepietowski, MD, PhD, Division of Dermatology, Venereology and Clinical Immunology, Faculty of Medicine, Wroclaw University of Science and Technology, Grunwaldzki Sq. 11, Wrocław 51-377, Poland (jacek.szepietowski@pwr.edu.pl).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.